New Launch15 May 2025, 09:18 am
Marksans Pharma's Subsidiary Gets Marketing Authorisation for Gabapentin Oral Solution in UK
AI Summary
Marksans Pharma Limited announces that its wholly owned subsidiary, Relonchem Limited, has received Marketing Authorisation for the product Gabapentin 50 mg/ml oral solution from the UK Medicines & Healthcare Products Regulatory Agency. Marksans Pharma Limited is a Mumbai-headquartered company engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulations in the global markets, with manufacturing facilities approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA.
Key Highlights
- Marksans Pharma's subsidiary, Relonchem Limited, receives Marketing Authorisation for Gabapentin 50 mg/ml oral solution from UK MHRA.
- The company is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulations in the global markets.
- Marksans Pharma's manufacturing facilities are approved by USFDA, UKMHRA, and Australian TGA.
- The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological, and Anti-allergies.
- Marksans Pharma is marketing these products globally.